.
.
.
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
- Gluten intolerance a significant risk factor
- Infectious disease of the uterus
- Absence of an individual specific disease